Clinical trial · Observational
Biomarkers for Diagnosis and Prognosis of Endometrial Carcinoma
Minimally and Non-invasive Methods for Early Detection and Progression of Endometrial Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Endometrial cancer (EC) is the most frequent gynecological malignancy but there is currently lack of both non-invasive diagnostic tools and novel markers to stratify patients based on their risk of future recurrence. Patient care could be improved by advances in these two aspects. In the present study, the investigators aim to identify diagnostic serum metabolite and protein biomarker signatures for early detection of cancer in asymptomatic high-risk population and prognostic biomarkers for selection of patients with poor prognosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cases
- description
- Women older than 18 years and diagnosed with endometrial cancer will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
- interventionNames
- Other: Blood sampling
- label
- controls
- description
- Women older than 18 years and with a benign endometrial disturbance will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
- interventionNames
- Other: Blood sampling
Primary outcomes (1)
- measure
- Creation of a diagnostic algorithm
- timeFrame
- 2020-2021
- description
- Blood metabolome and proteome will be analysed and bioinformatics/biostatistical analysis will be used to derive diagnostic algorithms based on blood metabolites, proteins and clinical data. Algorithms in the biomarker discovery study will be developed by comparing EC and patients with benign uterine pathologies.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria Cases: * endometrioid, serous, clear cell or mucinous endometrial cancer * dedifferentiated endometrial cancer * high grade or low grade endometrial cancer Inclusion Criteria Controls: * benign uterine diseases, e.g. myoma uteri, prolapsed uterus * prophylactic hysterectomy for Lynch syndrome Exclusion Criteria Cases: * atypical hyperplasia * other types of cancer * sarcoma uteri * previous diagnosis of endometrial cancer Exclusion Criteria Controls: * any cancer * benign ovarian diseases * previous EC * pregnancy at the time of enrollment
References
Publications (0)
Data not yet available